Neuberger Berman Group »

Inhibikase Therapeutics shares owned by Neuberger Berman Group

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Neuberger Berman Group from 13F filings

Historical chart of Neuberger Berman Group investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Neuberger Berman Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Neuberger Berman Group

Quarter filed Position value Share count Share price at filing
2026-06-30 $43k 21k 2.03

More positions owned by Neuberger Berman Group

Nvidia Corp Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Microsoft Corp Common (MSFT)
Alphabet Inc Class A A Common (GOOGL)
Alphabet Inc-cl C Common (GOOG)
Jpmorgan Chase & Co Common (JPM)
Eli Lilly & Co Common (LLY)
Ishares Core S&p 500 Etf Etf (IVV)
Broadcom Common (AVGO)
Asml Holding Adr Representing Nv Common (ASML)
Meta Platforms Inc Class A A Common (META)
Home Depot Common (HD)
Nextera Energy Common (NEE)
Analog Devices Common (ADI)

View all positions for Neuberger Berman Group

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Trails Edge Capital Partners
Fairmount Funds Management
BlackRock
ADAR1 Capital Management
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Millennium Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management

View all funds holding Inhibikase Therapeutics